Covered recipient · General Payments record
KEVIN L OLTMANNS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,944.04
- Reported across 274 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $322.84 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $91.51 | 6 |
| ABBVIE INC. | $68.15 | 2 |
| Astellas Pharma US Inc | $50.45 | 2 |
| Madrigal Pharmaceuticals | $25.32 | 1 |
| Abbott Laboratories | $19.39 | 1 |
| PFIZER INC. | $17.96 | 1 |
| Ferring Pharmaceuticals Inc. | $17.64 | 1 |
| Merck Sharp & Dohme Corporation | $16.52 | 1 |
| Janssen Pharmaceuticals, Inc | $15.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.39 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124986433 | CMS |
| ABBVIE INC. | $34.82 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105153977 | CMS |
| ABBVIE INC. | $33.33 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105153979 | CMS |
| Astellas Pharma US Inc | $23.45 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139313860 | CMS |
| Astellas Pharma US Inc | $27.00 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139347606 | CMS |
| Ferring Pharmaceuticals Inc. | $17.64 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137499801 | CMS |
| Janssen Pharmaceuticals, Inc | $15.90 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078141189 | CMS |
| Lilly USA, LLC | $16.38 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135111578 | CMS |
| Lilly USA, LLC | $14.48 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135104475 | CMS |
| Lilly USA, LLC | $13.64 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135111580 | CMS |
| Lilly USA, LLC | $14.21 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135130944 | CMS |
| Lilly USA, LLC | $17.61 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135104473 | CMS |
| Lilly USA, LLC | $15.19 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135130946 | CMS |
| Madrigal Pharmaceuticals | $25.32 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144177877 | CMS |
| Merck Sharp & Dohme LLC | $16.52 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141982157 | CMS |
| PFIZER INC. | $17.96 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131520599 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.